中 | EN

About Novel Peptide

Biomedical Development Platform

Immune Technology

As a company specializing in biomedical development platform with ingenious immunoassay techniques, Novel Peptide Bioscience Co., Ltd. was registered in Chongqing International Biological City, Banan District in 2020. With the technical support from innovative platforms at the state level and Chongqing Municipality's level such as Chongqing International Institute for Immunology, National Polypeptide Drugs Engineering Laboratory, China National Research Center for Immunobiological Products, National Pilot Production Center of Biological Industry Base and the Company's ingenious antigen engineering theory and technology system, the Company is capable of developing corresponding therapeutic drugs in multiple fields including chronic infectious diseases, tumors, autoimmune diseases and cognitive diseases.

Learn more

To be committed to developing innovative products meeting global market demands

To be an international leader in active immunotherapy

Preclinical Study

Pharmaceuticals Pilot and Scale-up Processes

Clinical Study

Application for Drug Registration

News & Trends

Get the latest news about Novel Peptide

  • Subject Recruitment Advertisement for Phase III Clinical Study of Therapeutic (Synthetic Peptide) Hepatitis B Vaccine (NHT210118)

  • Video Interpretation of Phase II Clinical Trial Results of Project NHT210118

  • NHT210118 Phase II Clinical Trial Paper is Published in Hepatology, the Best Journal on Liver Disease

  • NHT210118 Project Kick-off Meeting is held at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

  • Novel Peptide Bioscience Co., Ltd. Officially Starts its Phase III Clinical Trial of Project NHT210118

  • Novel Peptide Bioscience Co., Ltd. Acquires Jiangsu Mendel Gene Technology Co., Ltd.

Subject Recruitment Advertisement for Phase III Clinical Study of Therapeutic (Synthetic Peptide) Hepatitis B Vaccine (NHT210118)

Read more

Video Interpretation of Phase II Clinical Trial Results of Project NHT210118

See Annex 1: Phase II Promotion Video - 2.5 minutes

Read more

NHT210118 Phase II Clinical Trial Paper is Published in Hepatology, the Best Journal on Liver Disease

A Paper on Phase II Clinical Trial Results of Innovative Therapeutic Hepatitis B Vaccine (Mimogen-based) (ɛPA-44 or Ipa in Chinese) developed by the team led by Prof. Wu Yuzhang from the Army Medical University was published on August 15 in Hepatology (https:doi.org/10.1002/hep.32109), the best journal on liver disease. This study was completed by 15 top clinical sites in China, including the Peking University People''s Hospital. The corresponding author of the Paper was Prof. Wu Yuzhang from the

Read more

NHT210118 Project Kick-off Meeting is held at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

NHT210118 Project Kick-off Meeting is held at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Read more

Novel Peptide Bioscience Co., Ltd. Officially Starts its Phase III Clinical Trial of Project NHT210118

On February 4, 2021 (BJT), the Project "NHT210118" with the drug name "Therapeutic (Synthetic Peptide) Hepatitis B Vaccine" was officially started.

Read more

Novel Peptide Bioscience Co., Ltd. Acquires Jiangsu Mendel Gene Technology Co., Ltd.

On October 21, 2020 (BJT), Novel Peptide Bioscience Co., Ltd. declared that it had acquired Jiangsu Mendel Gene Technology Co., Ltd. and completed the transfer of Mendel''s all the projects and patents on the same day.

Read more

Join Us

Welcome to Join Novel Peptide

Morality-oriented Integrity and Professionalism Initiative and Dedication Teamwork

Recruitment position